Skip to main content
Premium Trial:

Request an Annual Quote

Personalized medicine: At DDT, NIH's Zerhouni makes case for new roads to discovery

Premium

Late this summer, NIH Director Elias Zerhouni gave the opening keynote address at the annual Drug Discovery Technology conference held in Boston, where he called on attendees from pharma, biotech, and the public sector to make inroads into the critical problems facing the drug discovery field.

“I think people underestimate our ignorance of these [biological] systems,” he told his audience. Noting the major public health challenges — 75 percent of the disease burden today is chronic disease, and emerging infectious diseases and obesity are rapidly becoming major healthcare issues as well — he reiterated some key components of his now-familiar “roadmap” for advancing biomedical research. Those include new pathways to discovery, new types of research teams, and an overhauled clinical enterprise, he said.

Discovery needs “better and more tools,” Zerhouni said, adding that bioinformatics, nanomedicine, and structural biology will be critical to that movement. Biological data of the future, he added, will have to be more complex than ever before, adding layers and layers of more detailed information. The idea of discovery itself needs to be broadened, he said, with “[expanded] concepts of assays, targets, and compounds.”

NIH is doing its part to help with that. Starting this month, Zerhouni said, the agency would launch a public database of chemical interactions and compounds, dubbed PubChem. NIH has also proposed starting up a program of Regional Translational Research Centers, which Zerhouni called “the crucible for new ideas.” These centers would strive to be multidisciplinary, heavily interactive research environments pairing basic science with clinical research and incorporating various elements such as biostatistics, pharmacogenetics, and genomics. That would in theory facilitate the kind of “larger, coordinated research sharing” that Zerhouni argues is essential to the future of discovery and improved healthcare overall, he said.

— Meredith Salisbury

 

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.